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High Mobility Group A are non-histone nuclear proteins that regulate chromatin plasticity and
accessibility, playing an important role both in physiology and pathology. Their activity is controlled by
transcriptional, post-transcriptional, and post-translational mechanisms. In this study we provide evidence
for a novel modulatorymechanism forHMGA functions.We show that HMGAs are complexed in vivo with
the histone chaperone nucleophosmin (NPM1), that this interaction requires the histone-binding domain
of NPM1, and that NPM1modulates both DNA-binding affinity and specificity of HMGAs. By focusing on
two human genes whose expression is directly regulated by HMGA1, the Insulin receptor (INSR) and the
Insulin-like growth factor-binding protein 1 (IGFBP1) genes, we demonstrated that occupancy of their
promoters by HMGA1 was NPM1-dependent, reflecting a mechanism in which the activity of these
cis-regulatory elements is directlymodulated byNPM1 leading to changes in gene expression. HMGAs need
short stretches of AT-rich nucleosome-free regions to bind to DNA. Therefore, many putative HMGA
binding sites are present within the genome. Our findings indicate that NPM1, by exerting a chaperoning
activity towards HMGAs, may act as a master regulator in the control of DNA occupancy by these proteins
and hence in HMGA-mediated gene expression.
C
hromatin accessibility is a main determinant in activating gene transcription. Besides histones, non-
histone chromatin proteins are among the main actors involved in regulating chromatin plasticity. An
important group of non-histone proteins is constituted by the high mobility group A (HMGA) family of
architectural transcription factors, which includes HMGA1a and HMGA1b protein isoforms, derived from
alternative splicing of the HMGA1 mRNA, and HMGA2, which is encoded by the separate but highly related
gene, HMGA21. HMGAs are considered oncofetal proteins, since they are highly expressed and play essential
roles during embryonic development and tumorigenesis. Although their expression is low in many adult tissues1,
HMGA1 is required for proper transcription of the insulin receptor (INSR) gene in both differentiated insulin
target cells in culture and in insulin target tissues from humans and adult mice2,3. Furthermore, we recently
showed that HMGA1, as a downstream target of the INSR signaling pathway, plays a key role in the nutritionally
and insulin-regulated transcription of genes involved in glucose metabolism, such as the IGFBP1 gene, as well as
the gluconeogenic genes PEPCK and G6Pase4.
HMGA proteins have no intrinsic transcriptional activity per se; rather, they have been shown to transactivate
promoters through mechanisms that facilitate the assembly and stability of stereospecific DNA-protein com-
plexes so-called ‘‘enhanceosomes’’, which promote gene transcription in response to extracellular and intracel-
lular signals. HMGAs perform this task by modifying DNA conformation and by recruiting transcription factors
to specific promoter regions, favouring DNA-protein and protein-protein interactions5,6, thus governing the
expression of an impressive number of mammalian genes7–9. Despite the fact that the mechanism(s) of their
regulation is still not completely known, HMGAs are finely modulated at different levels. In fact, in addition to
transcriptional regulation10–12, HMGA expression is post-transcriptionally regulated by miRNAs13–16 and pseu-
dogenes17, while their activity is under the surveillance of a series of post-translational modifications18.
Using a protein-protein interaction screening system, we previously identified three novel HMGA molecular
partners: the nuclear chaperones nucleophosmin (NPM1), nucleolin (NCL), and the histone chromatin assembly
factor 1 (CAF-1)19–21. Here we demonstrate that binding of NPM1 to HMGA proteins efficiently modulates
HMGA’s DNA-binding affinity and specificity towards two target gene promoters, the INSR and the IGFBP1
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promoters, whose functions are implicated in glucose metabolism
and the maintenance of glucose homeostasis. To our knowledge, our
results in the present work demonstrate a novel regulatory mech-
anism for the activity of HMGA proteins, which is mediated by
NPM1.
Results
NPM1 interacts in vivo with HMGA proteins. Using an affinity
chromatography-based proteomic approach, we previously reported
an in vitro interaction between HMGAs and NPM119. To test whe-
ther these factors can also associate in vivo, co-immunoprecipitation
assays were performed. HepG2 cell lysates were immunoprecipitated
with a-HMGA1 and a-HMGA2 antibodies and the immunocom-
plexes analyzed by western-blotting with an a-NPM1 antibody. As
shown in Fig. 1a, NPM1 associates with HMGA1 (lane 7), while
complex formation was not detected in the negative control (lane 5
– pre-immune serum). As a control, cell lysates were tested for the
expression ofHMGA1 andNPM1proteins; two different amounts of
lysate were used given the different signals obtained for HMGA1 and
NPM1 (lanes 1 and 3). The same approach has been used to
demonstrate the in vivo interaction between HMGA2 and NPM1
(Fig. 1b).
NPM1 is generally considered a nucleolar protein; however, in
accordance with literature data24, immunofluorescence analyses
clearly indicate that, despite its predominant localization in nucleoli,
NPM1 has also a nucleoplasmic localization in HepG2 cells
(Supplementary Fig. S1). Therefore, these experiments clearly dem-
onstrate that endogenous HMGA and NPM1 proteins share the
same nuclear sub-compartment and interact each other in vivo.
The central acidic clusters ofNPM1bind the basic protein-protein
interaction domain of HMGAs. Several functional domains have
been mapped within NPM1 aminoacidic sequence25,26: the N-
terminus contains an oligomerization domain (HoD); the central
portion has two highly acidic stretches (A2 and A3) separated by a
nuclear localization signal (NLS), whereas the C-terminal portion is
formed by a heterodimerization domain (HeD) mediating interac-
tions with other nuclear proteins and a nucleic acid-binding domain
(NBD) (Fig. 2). We mapped the NPM1 interaction domain using a
series of N- and C-terminal GST-fused NPM1 deletion mutants in
pull-down experiments with recombinant HMGA1a, HMGA1b, and
HMGA2 proteins (Fig. 2a). Results summarized in Fig. 2b clearly
show that NPM1/HMGAs interaction is abrogated when the central
portion of NPM1 is deleted (amino acid residues 118–186). In order
to assess whether this region itself bindsHMGAs, we performedGST
pull-down with GST-NPM1 117-186 and HMGA proteins (Fig. 2c).
Results show that, albeit with lower affinity with respect to the full-
length protein, the central portion of NPM1 containing the two
acidic clusters (A2 and A3 – Fig. 2b) is sufficient to interact with
HMGA proteins. Interestingly, these two clusters are responsible for
the histone chaperone activity of NPM127.Moreover, GST pull-down
experiments, using HA-tagged full length HMGA proteins, allowed
us to perform a quantitative comparison using the same antibody to
detect both proteins (HA-HMGA1a and HA-HMGA2), and to
determine that NPM1 displays almost the same affinity towards
the different HMGA proteins (supplementary Fig. S2).
As well as NPM1, HMGAs posses a modular organization. They
have three highly conserved and positively charged DNA-binding
domains (DBDs), a central protein-protein interaction domain
(PID), and an acidic C-terminal tail (Fig. 3). We previously demon-
strated by farwestern analyses that the region corresponding to the
protein-protein interaction domain of HMGA1 and HMGA2 is
necessary for NPM1 binding19,20. We performed mapping experi-
ments using HMGA1a protein employing both C- and N-terminal
deletion mutants in order to better clarify the domains used by
HMGA1 proteins to contact NPM1 (Fig. 3a). Results summarized
in Fig. 3b show that the truncated protein HMGA1a 1–79 retaining
this region is still able to bind to NPM1, whereas the truncated form
in which this region is deleted (1–51) is no longer able to perform it,
similarly to what already reported18,19. Importantly, by using
HMGA1a N-terminal deletion mutants, we demonstrated that the
N-terminal HMGA1a portion is fundamental for interacting with
NPM1, as well.
Interestingly, the interacting regions have opposite charges. The
region of NPM1 is highly negative and that of HMGAs is highly
positive, thus suggesting that NPM1/HMGA contact has an electro-
static contribution. To test this hypothesis, pull-down experiments
were performed using full-length GST-NPM1 and both HMGA1a
and HMGA2 proteins with increasing ionic strength. As shown in
Fig. 3c, salt concentration above 150 mM completely abolishes the
interaction, thus suggesting that the histone binding acidic clusters
of NPM1 are involved in the contact with HMGA proteins. Plasmid
DNA used to in vitro translate NPM1 is present in GST pull-down
experiments. Since both HMGAs and NPM1 are DNA binding
proteins1,28, to assess whether the detected interaction between these
two proteins was not mediated by DNA, we performed GST pull-
down experiments using increasing concentrations of EtBr, which
has been shown to disrupt DNA-dependent protein-protein con-
tacts29. As shown in supplementary Fig. S3, both HMGA1b and
HMGA2 bind to NPM1 in the presence of EtBr, thus demonstrating
that DNA does not mediate this interaction. The increment of
HMGA/NPM1 binding affinity that we observed with increasing
EtBr concentrations is probably caused by the change in the dielec-
tric constant of the binding buffer due to the presence of EtBr itself.
A direct HMGA/NPM1 interaction was further confirmed by GST-
Figure 1 | HMGAs and NPM1 associate in vivo. (a) Co-IP experiments
performed with cellular lysates from HepG2 cells. Protein lysate was
immunoprecipitated with a-HMGA1 specific antibody and NPM1 was
detected by western-blot using an a-NPM1 antibody (lane 7). Co-IP
performed with a pre-immune serum was included as a control of
specificity (lane 5). Lanes 1 and 3: inputs to check the presence of HMGA1
and NPM1 in cell lysates. (b) Co-IP was performed for HMGA2 protein as
described for panel a, using an a-HMGA2 specific antibody.
www.nature.com/scientificreports
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pull down experiments performed in the presence of DNase I (sup-
plementary Fig. S4).
NPM1 hampers HMGA/DNA binding.Histone chaperones aid the
process of histone removal/deposition and constitute temporary
reservoir for free histones30,31. In addition to histones27, NPM1 is
able to bind to other nuclear basic proteins, modulating their
DNA-binding activities32. Therefore, we investigated a possible role
of NPM1 on HMGA-DNA binding properties by electrophoretic
mobility shift assay (EMSA). Two different DNA probes were
used, HCRII and E3, which are both recognized by HMGAs and
correspond to the regulatory regions of HOXD9 and INSR genes,
respectively, whose activity is modulated by HMGAs2,23,33.
Figures 4a and b show EMSA experiments performed using the
HCRII probe with fixed amounts of HMGA proteins and increasing
quantities of GST-NPM1, while GST alone was used as a negative
control. The presence of GST-NPM1 (from 0.5 to 10 pmoles) leads
to an evident decrease of HMGA1a-HCRII complex formation
(Fig. 4a, lanes 2–7). Same results were obtained when HMGA2 was
used (Fig. 4b), while no effects were detected with increasing
amounts of GST alone (Fig. 4a and b, lanes 8–13). Both GST-
NPM1 and GST were not able to bind this DNA probe (lanes 14–
17). Figures 4c and d report the comparison of NPM1 effect on
HMGA1 binding affinity towards HCRII and E3 probes. Diffe-
rently from HCRII, E3 contains multiple binding sites for HMGA
proteins; therefore, two or more complexes can be detected when
E3 is incubated with increasing amounts of HMGAs22. Consistently
with the results shown in panel a, a further increase of NPM1 con-
centration (6 to 30 pmoles) causes a dramatic decrease of HMGA1a-
HCRII complex formation up to its disappearance (Fig. 4c, lane 8).
Interestingly, NPM1 behaviour with respect to HMGA1a-E3
complex formation seems to be different. The presence of GST-
NPM1, even at the lowest concentration (6 pmoles), completely
abolishes the formation of the second complex, while it strongly
promotes the formation of the first one (Fig. 4d, compare lane 2 with
lanes 9 and 20). On the contrary, the first complex formation is
inhibited only at the highest NPM1 concentrations (Fig. 4d, lane
8). These results demonstrate that NPM1 modulates the binding of
HMGA proteins to different DNA sequences. Since GST-NPM1 is
unable to bind any of theDNAprobes used, it is reasonable to assume
that this effect is dependent on a direct interaction between HMGA
and NPM1.
NPM1 modulates the level of HMGA1 at the endogenous
regulatory sequences of INSR and IGFBP1 genes. Next, we tested
whether the NPM1 activity obtained in vitro towards HMGA1 could
also be extended in vivo. In particular, we evaluatedHMGA1 binding
to the endogenous E3 region of the INSR gene promoter uponNPM1
Figure 2 | The NPM1 central region, containing two acidic clusters, mediates the interaction with HMGAs. (a) Protein-protein interaction mapping
experiment performed with GST pull-down assays using GST-fused N- and C-terminal truncated NPM1 forms and recombinant HMGA proteins
(HMGA1a: A1a; HMGA1b: A1b; HMGA2: A2). Bound proteins were visualized by western-blot using a-HMGA1 and a-HMGA2 antibodies. GST was
used as a negative control. (b) Schematic representation of protein-protein interaction mapping. The different NPM1 deletion mutants used and the
amino acid sequence of the HMGA-interacting region are reported. A1, A2, and A3: acidic regions. HoD and HeD: homo- and hetero-dimerization
domain, respectively. NLS: nuclear localization signal. NBD: Nucleotide binding domain. (c) Protein-protein interaction mapping experiment
performed with GST pull-down assay, using GST-fused NPM1 full length (1–295) and NPM1 117–186 with recombinant HMGA proteins. Bound
proteins were visualized by western-blot using a-HMGA1 and a-HMGA2 antibodies. GST was used as a negative control. Representative red ponceau
stained membranes are shown as quantity and integrity control of the GST fusion proteins used.
www.nature.com/scientificreports
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depletion in HepG2 cells. A similar study was carried out using the
promoter region of the IGFBP1 gene, which, as we demonstrated
before4 in this cell line, is also regulated by HMGA1. NPM1
expression was silenced in HepG2 cells using sequence-specific
siRNA and the in vivo binding of HMGA1 to both INSR and
IGFBP1 promoter regions was detected by ChIP, using an a-
HMGA1 specific antibody. As shown in Fig. 5, binding of HMGA1
to the endogenous INSR and IGFBP1 loci was significantly increased
in HepG2 cells exposed to siRNA against NPM1, thus indicating that
NPM1 modulates HMGA1 binding to its target DNA in living cells.
NPM1 modulates the activity of INSR and IGFBP1 regulatory
sequences and their endogenous gene expression levels. As stated
above, the binding of HMGA1 at the INSR and IGFBP1 promoters
has been associated with the transcriptional activation of these two
genes2,4. To see whether NPM1 had any functional effect on the INSR
and IGFBP1 genes, we transfected HepG2 cells with luciferase
reporter vectors harbouring the promoter region of either INSR or
IGFBP1, and promoter activity was assessed as luciferase activity in
cells, either silenced or not for NPM1 expression. Consistently with
data from ChIP showing the increase of HMGA1 occupancy on both
INSR and IGFBP1 gene promoters following cellular depletion of
NPM1, the reporter gene activity of the INSR and IGFBP1
promoters was significantly increased in HepG2 cells that
underwent NPM1 silencing (Fig. 6a), and this increase paralleled
the increase in INSR and IGFBP1 mRNA levels (Fig. 6b),
documenting a role of NPM1 in this scenario.
Discussion
In this study we provide evidence for a new mechanism underlying
the regulation of HMGA proteins activity, in which the molecular
chaperone NPM1, by binding HMGA protein species, finely mod-
ulates HMGA/DNA complex formation at the level of enhancer-
promoter sequences of target genes, hence affecting HMGA proteins
function and therefore their transcriptional activity. NPM1 is a his-
tone chaperone, which is involved at several levels in the process of
chromatin opening and nucleosome depletion during transcriptional
activation. NPM1 has been found to remove histone H1 from
Figure 3 | Multiple HMGA aminoacidic regions are involved in NPM1 binding. (a) Equivalent amounts of HMGA2, HMGA1b, HMGA1a, and
HMGA1a truncated forms were SDS-PAGE separated, blotted, and red ponceau stained. Membrane was then subjected to farwestern analysis. In vitro
transcribed, translated, and [35S]-radiolabelled full length NPM1 (1-295) was used as a probe. Interacting proteins were detected by fluorography.
(b) Schematic representation of farwestern results. HMGA forms used are schematically visualized and the aminoacid sequence of the NPM1-interacting
region is reported. DBD: DNA binding domain. PID: protein/protein interaction domain. Acidic tail: C-terminal acidic tail. (c) GST pull-down
experiments were performed with full length GST-fusedNPM1 and recombinant HMGA1a (A1a) andHMGA2 (A2) proteins at increasing ionic strength
conditions from 50 to 300 mM NaCl (lanes 3-7). GST was incubated with HMGA proteins at low or high (50 and 300 mM NaCl) ionic strength
conditions as a control (lanes 2 and 8). Equivalent amounts of HMGAproteins used in the GST pull-down experiments were loaded as references (lane 1).
Bound proteins were visualized by western-blot using a-HMGA1 and a-HMGA2 specific antibodies. A representative red ponceau stained membrane is
shown as quantity and integrity control of the GST fusion proteins used.
www.nature.com/scientificreports
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nucleosomal DNA34 and to disassemble acetylated nucleosomes35.
Interestingly, NPM1 is also involved in mediating the proper
deposition of histones and basic proteins in general onto DNA, thus
preventing the formation of non-specific protein-DNA aggrega-
tion27,31,32. In addition, NPM1 has been demonstrated to be involved
in themodulation of the activity of several transcription factors, such
as the Interferon regulatory factor-1 (IRF-1) and the transcription
factor Yin Yang 1 (YY1), whose DNA-binding and transcriptional
activities are alleviated by NPM136,37.
Herein we evaluated the effect of NPM1, on both INSR and
IGFBP1 promoters, clearly demonstrating that a decrease in NPM1
abundance is followed by an increase in the occupancy of promoter
DNA by HMGA1, resulting in an increase in promoter activity.
Consistently with these results, endogenous levels of both INSR
and IGFBP1 mRNAs were significantly upregulated upon siRNA
depletion of NPM1. Interestingly, EMSA experiments showed not
only a negative modulatory role of NPM1 towards HMGA-DNA
binding, but they also evidenced that the presence of NPM1 can
Figure 4 | NPM1 modulates HMGA/DNA complexes formation. (a,b) Comparison of HMGA1a and HMGA2 binding to the HCRII oligonucleotide.
(c,d) Comparison of HMGA1a binding to theHCRII and E3 oligonucleotides. HCRII: DNA sequence belonging to theHOXD9 gene promoter. E3: DNA
sequence belonging to the INSR gene promoter. EMSAs were performed with constant amounts of HMGA proteins (4 pmoles) and [c-32P] radiolabelled
DNA probes (0.1 pmoles) and increasing amounts of GST-NPM1 or GST. 0.5, 1, 2, 4, 6, and 10 pmoles of GST-NPM1 or GST were used in EMSAs
reported in panels a and b (lanes 2-7 and 8–13, respectively). 6, 10, 14, 18, 22, 26, and 30 pmoles were used in those reported in panels c and d (lanes 2–8
and 9–15). EMSAs performed with DNA probes and GST-NPM1 or GST (panels A and B, lanes 14–15 and 16–17: 0.5 and 10 pmoles, respectively; panels
C and D, lanes 16–17 and 18–19: 6 and 30 pmoles, respectively) constitute negative controls whereas those with DNA probes and HMGA proteins alone
are positive controls (panels a and b, lane 18; panels c and d, lane 20). The DNA probe alone is shown in panels a–d, lane 1. Results were visualized by
autoradiography. Panels a, b, c, and d show images grouped from the same gel and therefore they have the same exposure time.
www.nature.com/scientificreports
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selectively favor the formation of certain types of complexes with
respect to others, what represents a peculiarity of the histone chaper-
one protein family, which depends on chaperone concentration.
Indeed, as reported in the literature, DNA-binding specificity of basic
proteins (e.g. histone H1) is regulated by the abundance of NPM1,
which usually acts as a molecular chaperone driving the formation of
specific protein-DNA complexes. However, above a certain thresh-
old, NPM1 acts by sequestering basic proteins, thus preventing their
binding to DNA34. This is in line with the concept that NPM1 can
manifest opposite functional activities, depending on its expression
levels.
Overall, our results in the present study, must be interpreted tak-
ing into account at least three possible chaperoning roles of NPM1:
towards (i) HMGAs, (ii) core histones, and (iii) the linker histone
H127,31,32,34,35. Indeed, H1 and nucleosomes pose a steric hindrance to
the soft-landing of transcription factors on their own DNA binding
sites, having to be removed for the activation of gene transcription38.
Only when DNA is freely accessible, HMGA proteins can bind
directly to the minor groove of AT-rich DNA stretches and organize
the assembly of stereospecific nucleoprotein complexes, which are
essential for correct gene expression5,6. Therefore, it is reasonable to
assume that a triple contribution of NPM1 can be imagined in the
context of INSR and IGFBP1 expression, as well as in the context of
other HMGA-modulated genes. Based on these considerations and
our results, it may be tempting to consider a model on the modula-
tory role of NPM1 towards HMGA target genes. When NPM1 is
normally expressed, the formation of nucleosomes and higher order
chromatin structures driven by H1 is favoured. Conversely, when
NPM1 is overexpressed, such as in cancer cells, histones could be
removed fromDNA, leading to an open chromatin conformation. At
this point, NPM1 could act towards HMGA proteins, whose binding
affinity and specificity is also regulated by NPM1 (Fig. 7).
Consistently with our results from EMSAs, below a certain express-
ion threshold, NPM1 could selectively drive the formation of specific
complexes, whereas above a certain expression threshold, NPM1
could sequester HMGA1. This view is supported by the fact that
when NPM1 expression is downregulated by siRNA, the HMGA1
occupancy at the endogenous INSR and IGFBP1 loci is increased and
this increase is paralleled by an increase in the transcription rate of
these genes.
In this work, we evaluated the interplay that occurs between
NPM1 and HMGA1 in modulating the regulation of two glucose
homeostasis-related genes, such as the INSR and the IGFBP1 genes.
As we previously reported, HMGA1 plays an essential role in the
transcriptional regulation of these two genes2,23, and individuals with
defects in HMGA1 have increased susceptibility to type 2 diabetes
mellitus3,17,39,40 and metabolic syndrome41, a cluster of individual
disorders all predisposing to cardiovascular disease. On the other
hand, the involvement of HMGA proteins in cancer is well known1,
as it is known the involvement of both the INSR and IGFBP1 in cell
proliferation and neoplastic transformation42,43. Interestingly, both
NPM1 and HMGAs are highly expressed in tumor cells. Thus,
Figure 5 | NPM1 modulates the in vivo INSR and IGFBP1 gene promoter occupancy of HMGA1. ChIP analyses for the evaluation of HMGA1
occupancy at the level of INSR (upper panel) and IGFBP1 (lower panel) promoters. Both qPCR data (histograms) and representative electrophoretic
analyses of PCR-amplified immunoprecipitated DNAs are shown. ChIP analyses were performed inHepG2 cells pretreated withNPM1 siRNA (lane 7) or
control siRNA (lane 6), using an a-HMGA1 specific antibody. The relative quantity of promoter enriched by ChIP (HMGA1 binding region) was
quantified by qPCR and expressed as a percentage of the input DNA (lanes 1 and 8, in both panels). On the right side of the panels (lanes 9 and 10), ChIP
analyses evaluating no-HMGA1-binding-site regions at the level of INSR and IGFBP1 promoters are shown as negative controls. Lanes 2, 3, 4, and 5 show
specificity controls for ChIPs. Lane 1 and 8 show inputDNA fromHepG2 cells treated with control siRNA orNPM1 siRNA, respectively. All analyses were
performed in triplicate and data are presented as mean 6 s.e.m. *P , 0. 05 versus control siRNA treated cells (lane 6).
www.nature.com/scientificreports
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abnormalities in the interplay of NPM1 with HMGA proteins, by
affecting INSR and IGFBP1 gene regulation,might play a role in these
conditions.
In conclusion, our results demonstrate a new post-translational
regulatory mechanism controlling HMGA activities. This obser-
vation might have relevance to the pathophysiology of insulin-res-
istant syndromes and other pathological conditions where HMGAs
have been implicated.
Methods
Co-immunoprecipitation (Co-IP). HepG2 cells were cultured in DMEM 10% fetal
bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL
streptomycin. Cells were grown at 37uC in humidified 5% CO2 incubator, collected
under subconfluence conditions, harvested in PBS, and lysed in Co-IP lysis buffer
(25 mM Tris/HCl Ph 8, 0.5% v/v NP40, 10% v/v Glycerol, and 125 mM NaCl)
supplemented with 1 mM PMSF, 1 mM NaVO3, 5 mM NaF, 10 mM
Na(C3H7COO), and protease inhibitors cocktail (Sigma). Lysates were left for
15 minutes at 4uC and then sonicated (six times: 10 seconds pulse with 20 seconds
pause, 30% power – Branson Digital Sonifier 250). Cellular debris was eliminated by
centrifugation (15000 g, 10 min). Protein concentration was estimated by the
Bicinconinic Acidmethod. 1 mg of lysate was used to perform a single Co-IP in 1 mL
final volume (Co-IP lysis buffer) using 30 mL of Sepharose G protein resin (GE-
Healthcare). Equal amounts of a-HMGA1 or a-HMGA2 antibody and pre-immune
serum were previously immobilized on the resin. Resins were incubated with Co-IP
lysis buffer supplemented with 1 mg/mL BSA for 1 h at 4uC and washed three times
with Co-IP lysis buffer. Resins and lysates were incubated for 3 h at 4uC. Unbound
proteins were removedwith 3washes usingCo-IP lysis buffer. After elimination of the
washing buffer, proteins were eluted by SDS sample buffer (40 mL). 8 mL of the eluted
proteins were used for western-blot analyses. Inputs were obtained by directly
conditioning a part of cell lysate with SDS sample buffer (75 and 2.5 mg for the
detection of HMGAs and NPM1, respectively). Inputs and Co-IP proteins were
western-blot analyzed with standard procedures using a-HMGA1, a-HMGA2, and
a-NPM1 antibodies. a-NPM1 antibody was a monoclonal antibody purchased from
Abcam (# ab10530), whereas a-HMGA1 and a-HMGA2 antibodies were rabbit
polyclonal antibodies obtained in our laboratory.
GST pull-down and farwestern assays. Recombinant GST-fusion proteins and
HMGA proteins were expressed and purified as already described19. Plasmid vectors
encoding for GST-fusion NPM1 forms (1–295, 1–259, 1–186, 1–117, 187–295, and
260–295) were kindly provided by P.G. Pelicci. pGEX 4T3 GST-NPM1 117-186 was
generated by PCR with pGEX 4T3 GST-NPM1 1-295 as a template and the following
primers: for 59-GGCTGTGAATTCAGTAGCTGTGGAGGAA-39; rev 59-
TATCGGCTCGAGTCATCAAGCTTCCTCATCATC-39. In vitro production and
radiolabeling of NPM1, GST pull-down, and farwestern experiments were performed
essentially as already described19.
EMSAs. GST and GST-NPM1 1–295 were produced as described above and eluted
from Glutathione Sepharose 4B resin (GE Healthcare) by 50 mM Tris/HCl pH 8,
10 mM GSH. The indicated amounts of GST and GST-NPM1 1–295 (0.5, 1, 2, 4, 6,
and 10 or 6, 10, 14, 18, 22, 26, and 30 pmoles) were incubated with 4 pmoles of
HMGA proteins in 25 mM Tris/HCl pH 8, 5 mM GSH for 10 min at 4uC in a final
volume of 8 mL. Radiolabelled DNA (0.1 pmoles) was then added to the protein
mixture for an additional 10 minutes incubation in 180 mM NaCl, 1 mM MgCl2,
0.01% w/v BSA, 8% v/v glycerol, 10 mM Tris/HCl pH 7.9 (20 mL final volume) prior
to gel loading. EMSAs were carried out essentially as previously described22. DNA
probes (only the upper strand sequences are shown): E3: 59-AGAAAAACTCCAT-
CTAAAAAAAAAAAAAAAAAAAAAAAAAAACA-39; HCRII: 59-GACACATT-
AATCTATAATCAAATA-39.
Figure 6 | NPM1 modulates INSR and IGFBP1 gene promoter activities
and their in vivo transcriptional outputs. (a) HepG2 cells, pretreated with
NPM1 siRNA or control siRNA, were transfected with luciferase vectors
containing the promoter regions of either INSR (INSR-Luc) or IGFBP1
(IGFBP1-Luc). Values are expressed as factors by which induced activity
increased above the level of luciferase activity obtained in control siRNA
transfections with either INSR-Luc or IGFBP1-Luc reporter, which is
assigned an arbitrary value of 1. Western blot analyses of NPM1 in each
condition are shown. b-actin, control of protein loading. Data are
represented as mean 6 s.e.m. from three independent experiments
(*P, 0. 05 versus cells treated with control siRNA). (b) qRT-PCR analyses
of INSR and IGFBP1 expression inHepG2 cells transiently transfected with
NPM1 siRNA or control siRNA after 72 hours. NPM1 mRNA expression
level is shown as a control for NPM1 silencing efficacy. Data are
represented as mean 6 s.e.m. from three independent experiments
(*P , 0. 05 versus cells treated with control siRNA).
Figure 7 | A model for the NPM1 modulatory role towards HMGA1. By
directly binding to HMGA1 proteins, NPM1 could modulate the
occupancy and binding specificity of these transcriptional architectural
factors with respect to AT-stretches at the level of promoters/enhancers.
www.nature.com/scientificreports
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ChIP. hIP was performed in cultured HepG2 cells, pretreated with either SMART
pool ON TARGET Plus NPM1 siRNA (Dharmacon) or control siRNA as described
previously4. Sequence-specific primers for IGFBP1 and INSR gene promoters used for
PCR and qPCR amplification are listed in Supplementary Information.
Plasmid transfections and Luciferase assay. Recombinant Luc reporter constructs
containing either human INSR-E323 or IGFBP1 promoter4 were transiently
transfected into HepG2 cells, using LipofectAMINE 2000 reagent (Invitrogen Life
Technology Corporation, Carlsbad, Calif. USA), in the presence of siRNA targeting
human NPM1 (SMART pool ON TARGET Plus NPM1 siRNA - Dharmacon) or
nonspecific siRNAwith a similar GC content (ON-TARGETplus Non-targeting Pool
- Dharmacon). After knockdown for 72 h, the cells were prepared for analysis and
luciferase activity was assayed in a luminometer (Turner Biosystems), using the dual-
luciferase reporter assay system (Promega, Madison, Wis., USA). Renilla control
vector served as an internal control of transfection efficiency, together with
measurements of protein expression levels.
Quantitative Reverse Transcription PCR (qRT-PCR). For qRT-PCR, total cellular
RNA was extracted from cells using the RNAqueous-4PCR kit and subjected to
DNase treatment (Ambion). RNA levels were normalized against 18S ribosomal RNA
in each sample, and cDNAs were synthesized from 2 mg of total RNA using the
RETROscript first strand synthesis kit (Ambion). Primers were designed according to
sequences from the GenBank database: human IGFBP1 (NM_000596.2): for 59-
CATTCCATCCTTTGGGAC-39; rev 59-ATTCTTGTTGCAGTTTGGCAG-39.
human INSR (NM_000208.2) for 59-TTTGGGAAATCACCAGCTTGGCAGAAC-
39; rev. 59-AAAGCTGGGGTGCAGGTC GTCCTTG-39. A real-time thermocycler
(Eppendorf Mastercycler ep realplex ES) was used to perform quantitative PCR. In a
20 mL final volume, 0.5 mL of the cDNA solution was mixed with SYBR Green
RealMasterMix (Eppendorf), and 0.3 mM each of sense and antisense primers. The
mixture was used as a template for the amplification by the following protocol: a
denaturing step at 95uC for 2 min, then an amplification and quantification program
repeated for 45 cycles of 95uC for 15 s, 55uC for 25 s, and 68uC for 25 s, followed by
the melting curve step. SYBR Green fluorescence was measured, and relative
quantification was made against ribosomal protein S9 cDNA used as an internal
standard.
Statistics. Statistical significance was evaluated using a 2-tailed Student’s t test. P ,
0.05 was considered significant. All bar graph data shown represent mean 6 s.e.m.
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